Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6051 in Patients With Advanced Solid Tumors
NCT07591285Phase 1Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label, single-arm trial of SYS6051 in solid tumor, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events and 3 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
SYS6051
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07591285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591285.